45.79
price down icon0.13%   -0.06
after-market Dopo l'orario di chiusura: 45.79
loading

Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie

pulisher
02:05 AM

Kymera Therapeutics Inc. Stock Analysis and ForecastSuperior returns - PrintWeekIndia

02:05 AM
pulisher
03:38 AM

Will Kymera Therapeutics Inc. stock benefit from AI tech trendsOutstanding trading profits - jammulinksnews.com

03:38 AM
pulisher
Jul 24, 2025

What drives Kymera Therapeutics Inc. stock priceOutstanding growth strategies - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 23, 2025

Is Kymera Therapeutics Inc. a good long term investmentFree Stock Market Query - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Kymera Therapeutics Inc. stockHigh-profit stock alerts - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 18, 2025

What makes Kymera Therapeutics Inc. stock price move sharplyAlpha Stock Ideas - beatles.ru

Jul 18, 2025
pulisher
Jul 18, 2025

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? - Yahoo Finance

Jul 18, 2025
pulisher
Jul 17, 2025

Goldman Sachs Initiates Coverage on Kymera Therapeutics as Early-Stage Biotech with Potential Upside of 33.75% - AInvest

Jul 17, 2025
pulisher
Jul 15, 2025

How Kymera Therapeutics Inc. stock performs during market volatilityFree Risk Assessment Services - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Forecasting the Future: Targeted Protein Degradation - openPR.com

Jul 10, 2025
pulisher
Jul 10, 2025

Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating - Insider Monkey

Jul 10, 2025
pulisher
Jul 08, 2025

Brookline Capital Markets Sticks to Their Buy Rating for Kymera Therapeutics (KYMR) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 07, 2025

Kymera Therapeutics stock price target lowered to $65 at Brookline Capital - Investing.com Canada

Jul 07, 2025
pulisher
Jul 06, 2025

(KYMR) Investment Analysis - news.stocktradersdaily.com

Jul 06, 2025
pulisher
Jul 03, 2025

Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion - Investing.com Canada

Jul 03, 2025
pulisher
Jul 02, 2025

Kymera Therapeutics (KYMR) director group buys $13.9 million in stock By Investing.com - Investing.com South Africa

Jul 02, 2025
pulisher
Jun 30, 2025

Kymera Therapeutics: Baker Bros acquire $28.8m in shares By Investing.com - Investing.com South Africa

Jun 30, 2025
pulisher
Jun 30, 2025

Kymera Therapeutics: Baker Bros acquire $28.8m in shares - Investing.com

Jun 30, 2025
pulisher
Jun 30, 2025

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer - MSN

Jun 30, 2025
pulisher
Jun 27, 2025

Oppenheimer Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

Oppenheimer Adjusts Price Target for Kymera Therapeutics (KYMR) - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

KYMR: Key Insights on Recent Developments | KYMR Stock News - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

Nuclear stocks, Kymera Therapeutics, Estee Lauder - TradingView

Jun 27, 2025
pulisher
Jun 27, 2025

Gilead and Kymera in pact to develop cancer drugs - MSN

Jun 27, 2025
pulisher
Jun 26, 2025

Kymera Therapeutics (KYMR) Target Price Lowered by Wells Fargo | KYMR Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

Kymera Therapeutics Announces Proposed Public Offering | KYMR St - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update - TradingView

Jun 26, 2025
pulisher
Jun 25, 2025

Kymera Therapeutics launches $250 million public stock offering - Investing.com

Jun 25, 2025
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):